2007;56;5:641 -8. Heat Biologics, Inc. Investigational Product: V iagenpumatucel -L Protocol HS110 -201 CONFIDENTIAL Version 4.0; 29 -Oct-2014 Page 83 of 84 41 Raez, LE, Walker GR, Baldie P, Fisher E, Gom ez JE, Tolba K, Santos ES, Podack, ER. CD8 T cell response in a phase I study of therapeutic vaccination of advanced NSCLC with allogeneic tumor cells secreting endoplasmic reticulum -chaperone gp96 -Ig-peptide complexes. Advances in Lung Cancer 2013;2:9 -18. 42 Syrigos K et al. The Need for Third -line Treatment in Non -small Cell Lung Cancer: An Overview of New Options. Anticancer Research 2011;31:649 -660. 43 Chu D et al. Patient attitudes towards chemotherapy as assessed by patient versus physician: a prospecti ve observational study in advanced non smallcell lung cancer. Lung Cancer 2007; 56: 433 -443. 44 Hirose T et al. Patients preferences in chemotherapy for advanced non -small cell lung cancer. Intern Med 2005; 44: 107 -113. 45 Murillo J & Koeller J Chemotherapy given near the end of life by community oncologists for advanced non-small cell lung cancer. Oncologist 2006; 11: 1095 -1099. 46 Soo Lee J et al. Vandetanib Versus Placebo in Patients With Advanced Non –Small -Cell Lung Cancer After Prior Therapy With an Epide rmal Growth Factor Receptor Tyrosine Kinase Inhibitor: A Randomized, Double -Blind Phase III Trial (ZEPHYR). J Clin Oncol 2012; 30:1114 -1121. 47 A 3rd/4th Line Placebo -controlled Trial of Sorafenib in Patients With Predominantly Non Squamous Non-Small Cell L ung Cancer (NSCLC). (MISSION ): http://www.clinicaltrials.gov/ct2/show/results/NCT00863746?term=MISSION&rank=1. 48 Morgensztern D et al. Third -line chemotherapy with gemcitabine or docetaxel in patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2005; 23(16S): Abstr no. 7298. 49 Burris H. Shortcomings of current therapies for non -small -cell lung cancer: unmet medical needs. Oncogene 2009;28 (Suppl. 1):S4 –S13. 50 NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). non -small ce ll lung cancer. National Comprehensive Cancer, Network 2012.v2; 2012. 51 Gerber DE, Minna JD. ALK inhibition for non -small cell lung cancer: from discovery to therapy in record time. Cancer Cell 2010;18:548 –51. 52 Garassino M et al. Erlotinib versus docetaxe l as second -line treatment of patients with advanced non - small -cell lung cancer and wild -type EGFR tumours (TAILOR): a randomised controlled trial. The Lancet Oncology 2013; 14: 981 – 988. 53 Okano Y. et al. Randomized phase III trial of erlotinib (E) vers us docetaxel (D) as second - or third -line therapy in patients with advanced non -small cell lung cancer (NSCLC) who have wild -type or mutant epidermal growth factor receptor (EGFR): Docetaxel and Erlotinib Lung Cancer Trial (DELTA). J Clin Oncol [ASCO abstr act 8006]. 2013;31(15S):8006. 54 Shaw A, et al. Clinical features and outcome of patients with non -small -cell lung cancer who harbor EML4 -ALK. J Clin Oncol 2009;27:4247 -4253. 55 Langer C, Mok T, Postmus P. Targeted agents in the third -/fourth -line treatment of patients with advanced (stage III/IV) non -small cell lung cancer (NSCLC). Cancer Treatment Reviews 2013; 39: 252 –260. 56 Girard N et al . Third -line chemotherapy in advanced non -small cell lung cancer: identifying the candidates for routine practice. J Th orac Oncol 2009;4:1544 –9. 57 Mita A et al. Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function. J Clin Oncol 2006;24: 552 –562. 58 Stinchcombe T, Socinski M. Considerat ions for second -line therapy of non -small cell lung cancer. Oncologist 20008; 13(Suppl 1): 28 –36. 59 Hanna N et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non -small -cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004; 22: 1589 –1597. 60 Crawford J et al. Chemotherapy -induced neutropenia: risks, consequences, and new directions for its management. Cancer 2004; 100: 228 –237. 61 Ghiringhelli F, Larmonier N, Schmitt E, et al. CD4+CD25+ regulatory T cells supp ress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol.